Company: NIVFW
Filing Date: 2025-08-21
Form Type: DRS
Source: 0001213900-25-079301
Chunk: 99

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-21
Form: DRS
Chunk 99
---
, which could cause its results of operations to fall below the
expectations of securities analysts and investors, resulting in a decline in the market price of its Class A Ordinary Shares and Warrants.

NewGenIvf is subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject it to criminal or civil liability and harm its business, financial condition and results of operations.

NewGenIvf is subject to the
Anti-Money Laundering Act B.E. 2542 (1999) of Thailand, the Act Supplementing the Constitution Relating to the Prevention and Suppression
of Corruption B.E. 2561 (2018) of Thailand, and the Penal Code of Thailand, domestic bribery laws, and other anticorruption and anti-money
laundering laws in the countries in which it conducts activities. Anti-corruption and anti-bribery laws have been enforced aggressively
in recent years and are interpreted broadly to generally prohibit companies, their employees and their third-party intermediaries
from authorizing, offering, or providing, directly or indirectly, improper payments or benefits to recipients in the public or private
sector. If NewGenIvf expands its business and sales and to the public sector, it may engage with business partners and third-party intermediaries
to market its services and to obtain for it the necessary permits, licenses, and other regulatory approvals. In addition, NewGenIvf or
its third-party intermediaries may have direct or indirect interactions with officials and employees of government agencies or state-owned
or affiliated entities. NewGenIvf can be held liable for the corrupt or other illegal activities of these third-party intermediaries,
its employees, representatives, contractors, partners and agents, even if it does not explicitly authorize such activities. Detecting,
investigating, and resolving actual or alleged violations of anti-corruption laws can require a significant diversion of time, resources,
and attention from senior management. In addition, noncompliance with anti-corruption, anti-bribery, or anti-money laundering laws could
subject it to whistleblower complaints, investigations, prosecution, enforcement actions, sanctions, settlements, fines, damages, other
civil or criminal penalties or injunctions, suspension or debarment from contracting with certain persons, reputational harm, adverse
media coverage, and other collateral consequences. If any subpoenas or investigations are launched, or governmental or other sanctions
are imposed, or if NewGenIvf does not prevail in